• Skip to main content
  • Skip to footer
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Business

October 19, 2023

CN Bio showcased in PwC UK’s ‘Life Sciences Future 50’ report 2023

We are delighted to announce that we are showcased as one of the 50 companies in PwC UK’s 'Life Sciences Future 50' report. The report illustrates

Category iconBusiness

June 24, 2021

Cell4Pharma enters supply agreement with CN Bio

Today, we signed a supply agreement with Dutch Company Cell4Pharma to access their industry-validated conditionally immortalized Renal Proximal Tubule

Category iconBusiness

March 2, 2018

CN Bio MicroMix to be featured at AACR

Dr David Hughes, Chief Technical Officer at Organ-on-Chip specialist CN Bio Innovations will be presenting a poster at the American Association for

Category iconBusiness

February 22, 2018

PharmaVentures interview: Will Organ-on-Chip technology provide the data regulators need in the future?

As new drug treatments are developed, quicker and much more precise technology which predicts the effect these chemical and biological substances have

Category iconBusiness

December 15, 2017

R&D 100 Award won by Vanderbilt team for tech being developed with CN Bio

A cell-culture technology now being developed by London biotech CN Bio Innovations and its global pharmaceutical company partner, has won one of the

Category iconBusiness

June 13, 2016

MIT and CN Bio to showcase world’s first 7 organ “Human-on-a-Chip” at Organ-On-Chip congress

MIT and CN Bio Innovations today announced that the world’s first 7-organ “Human-on-a-Chip” platform will be showcased at the Organ-on-Chip congress

Category iconBusiness

June 6, 2016

CN Bio Sponsors the Organ-On-Chip world congress in Boston

CN Bio Innovations Ltd, an expert in developing human organs-on-chips to test and develop therapeutics for serious diseases, is proud to be the

Category iconBusiness

January 4, 2016

CN Bio appoints Emma Sceats as CEO

CN Bio Innovations are delighted to announce the appointment of Dr Emma Sceats as Chief Executive effective 1st January 2016. Dr David Scales will

Category iconBusiness

November 2, 2015

Imperial College London to present HBV data on CN Bio immune-competent liver model at AASLD The Liver Meeting

New advances in the pre-clinical evaluation of Hepatitis B therapies Welwyn Garden City, UK, 2 Nov 2015: CN Bio Innovations Ltd, an expert in

Category iconBusiness

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development June 10, 2025
  • CN Bio expands access to OOC solutions for APAC customers with distributor agreement in South Korea May 20, 2025
  • Microphysiological systems for mAbs development: how do they address animal limitations? May 1, 2025
Cyber Essentials Logo